Abstract: The present invention relates to novel compounds of the formula (I), in which R is is hydrogen or hydroxy, that can be obtained by fermentation of the microorganism strain Corallococcus coralloides ST201330 (DSM 24989).

Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.

Abstract: The present invention relates to a method for recombinant production of Labyrinthopeptins and functional derivatives thereof. Moreover, the present invention relates to novel functional derivatives of Labyrinthopeptins.

Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.

Abstract: The disclosure relates to a compound of the formula (I) wherein R1 is H, C(O)—(C1-C6)alkyl or C(O)—O—(C1-C6)alkyl; R2 is OH, NH2, NH—(C1-C6)alkyl, NH—(C1-C4)alkylene-phenyl or NH—(C1-C4)alkylene-pyridyl; R3 and R4 are independently of each other H or OH, or R3 and R4 together are ?O; and m and n are independently of one another 0, 1 or 2; in any stereochemical form, or a mixture of any stereochemical forms in any ratio, or a physiologically acceptable salt thereof, obtainable from Actinomadura namibiensis (DSM 6313), and its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.

Abstract: The invention relates to the use of a compound of the formula (I) for the treatment of bacterial infections caused by mycobacteria, nocardia or corynebacteria, wherein E is phosphorus; X1, X2 and X3 are oxygen; and R1 and R2 are as defined in the specification.

Abstract: The disclosure relates to a compound of the formula (I) wherein m and n are independently of one another 0, 1 or 2, obtainable from Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.

Abstract: The invention relates to the use of a compound of the formula (I) for the treatment of bacterial infections caused by mycobacteria and related microorganisms, such as tuberculosis, leprosy, nocardiosis, diphtheria, pulmonary mycobacterial infection, cutaneous mycobacterial infection, atypical mycobacterial infection and mycobacteriosis.

Abstract: The present invention provides novel phenalenone derivatives of formula (I) which are formed by the microorganism Penicillium herquei Bainer & Sartory, DSM 14142, during fermentation.

Abstract: The present invention relates to spirobenzofuran lactam derivatives of the formula I which are formed during fermentation by the microorganism Stachybotris atra ST002348, DSM 14952, processes for their preparation, their use as pharmaceuticals, and the microorganism Stachybotris atra ST002348, DSM 14952.

Abstract: The present invention relates to 2-phenylbenzofurans of formula (I) which are formed, during fermentation, by the microorganism Aspergillus flavipes ST003878 (DSM 15290), to a process for preparing them and to their use as pharmaceuticals for the treatment and/or prophylaxis of bacterial infectious diseases or mycoses.

Abstract: The present invention relates to novel hydroxyphenylundecane derivatives of the formula (I), a method for the preparation of said compounds by cultivation of the fungus Cryphonectria parasitica, DSM 14453, and their use as pharmaceuticals, i.e. for the treatment of Alzheimer's Disease, Parkinson's Disease, Huntington's Diseases, stroke, psychosis and/or depressions.

Abstract: The present invention relates to compounds of the formula (I) which are formed by the microorganism ST 003236 (DSM 14476) during fermentation, to a process for preparing and derivatizing them, to a pharmaceutical which comprises a compound of the formula (I) and to the use thereof for producing a pharmaceutical.

Abstract: Coniosulfides and their derivatives, processes for preparing them, and their use as pharmaceuticals. The present invention relates to the use of a compound of the formula (VI) for producing a pharmaceutical for the treatment and prophylaxis of degenerative neuropathics or of Alzheimer's disease.

Abstract: The present invention relates to compounds of the formula which are formed during fermentation by the microorganism Coniochaeta ellipsoidea Udagawa, DSM 13856, or by one of its mutations and/or variants, and chemically derivatized if appropriate. The invention furthermore relates to a process for preparing compounds of the formula (I), and to their use as pharmaceuticals. In addition, the invention relates to the use of a compound of the formula (VI) for producing a pharmaceutical for the treatment and prophylaxis of degenerative neuropathics or of Alzheimer's disease.

Abstract: The present invention relates to 2-phenylbenzofurans of formula (I) which are formed, during fermentation, by the microorganism Aspergillus flavipes ST003878 (DSM 15290), to a process for preparing them and to their use as pharmaceuticals for the treatment and/or prophylaxis of bacterial infectious diseases or mycoses.

Abstract: The present invention relates to novel compounds of the formula I in which R(1), R(2), R(3) and R(4) are, independently of each other, hydrogen or an alkyl radical. The compounds of the formula I are inhibitors of KDR kinase and, due to their antiangiogenic effect, are suitable for preventing and/or treating malignant diseases. The compounds of the formula I can be obtained by fermenting the microorganism Eurotium echinulatum Delacroix (DSM 13872) or by chemically derivatizing the compounds which are obtained after fermenting said microorganism. The invention consequently also relates to a process for preparing the compounds of the formula I, to the use of the compounds of the formula I for preparing a pharmaceutical for treating malignant diseases and diseases which can be treated by inhibiting KDR kinase, and also to pharmaceutical preparations which have a content of at least one compound of the formula I.

Abstract: The present invention provides novel drechsleranol compounds of formula (I) which are formed by the microorganism Drechslera australlensis, ST 003360, DSM 14093, or a fungus ST 004112, DSM 14524, during fermentation. A process for their preparation, pharmaceutical compositions containing said drechsleranols their use for the treatment and/or prophylaxis of degenerative neuropathies, such as, Alzheimeu's disease, or psychiatric disorders, such as depression, sleep disturbance or seasonal affective disorder, and their use as chelating agents or antioxidants are also disclosed and claimed.

Abstract: The present invention relates to spirobenzofuran lactam derivatives of the formula I 1

Abstract: The present invention relates to novel hydroxyphenylundecane derivatives of the formula (I), 1